Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors
European Journal of Cancer, 10/23/09
Skinner R et al. – Platinum nephrotoxicity did not change significantly over 10years. Its severity was correlated to older age at treatment, and at some time points to higher cisplatin dose rate and higher cumulative carboplatin dose.
Methods- 63 children treated with platinum (27 cisplatin, 24 carboplatin and 12 both) were studied at end of treatment 1year and 10years later
- No child received ifosfamide
- GFR, serum calcium and magnesium (Mg) were measured, and total nephrotoxicity score (Ns) was graded
- No significant overall change in renal function over time in any treatment group (cisplatin, carboplatin or combined)
- Apart from marginally reduced median GFR (84ml/min/1.73m2) and Mg (0.68mmol/l) at End of cisplatin, median GFR, Ca and Mg were normal at all times in each group
- At 10years, GFR was < 60ml/min/1.73m2 in 11%, Ns grade severe in 15% and oral Mg supplements were required in 7% cisplatin patients
- After cisplatin, older age at treatment correlated with lower GFR at 10years , and higher Ns at End and 10years
- After carboplatin treatment, older age associated with lower GFR at all times, and with higher Ns at End and 1y
- Higher cisplatin dose rate (> 40mg/m2/day) was associated with higher Ns at 1y and higher carboplatin dose with lower Mg at 1y and with higher Ns at 1 and 10y
Today in Pediatric Heme/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia
Journal of Clinical Oncology, 11/09/09
Medulloblastoma in childhood: revisiting intrathecal therapy in infants and children
Cancer Chemotherapy and Pharmacology, 10/29/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
Annals of Oncology, 11/06/09
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09
Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia
Journal of Clinical Oncology, 11/09/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


